Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
Sarah P. Blagden(Churchill Hospital), Andrew R. Clamp, Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Timothy Perren(Royal Marsden NHS Foundation Trust), Graham Dark(Freeman Hospital), Jae‐Weon Kim(Seoul National University Hospital), Andrew Dean, Richard Kaplan(University College London), Ian R. White(MRC Clinical Trials Unit at UCL), Elizabeth C James(MRC Clinical Trials Unit at UCL), Jonathan A. Ledermann(Cancer Institute (WIA)), Helena Earl(University of Cambridge), Iain A. McNeish(Beatson West of Scotland Cancer Centre), Christopher Poole(Guy's Hospital), Dearbhaile M. O’Donnell, Lesley Howells, Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust), Jane Hook(University of Leeds), Adrian Cook(University College London)
Cited by 37
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people
|The Lancet|2014|1.6k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k